Skip to main content
ViroGates A/S logo

ViroGates A/S — Investor Relations & Filings

Ticker · VIRO ISIN · DK0061030574 LEI · 5493007TX8XS56RMZD94 ST Manufacturing
Open in API
Filings indexed 162 across all filing types
Latest filing 2021-03-24 Report Publication Anno…
Country DK Denmark
Listing ST VIRO

About ViroGates A/S

https://www.virogates.com/

ViroGates A/S is an in-vitro diagnostics company that develops and markets blood tests to measure chronic inflammation. The company's core product line, suPARnostic®, is based on the suPAR (soluble urokinase Plasminogen Activator Receptor) biomarker. This biomarker measures the activation level of the immune system to predict patient outcomes, disease risk, and the severity of chronic inflammation. The primary applications for suPARnostic® products are in hospitals for patient triaging, in the longevity market for health assessment, and in clinical research. The technology aims to improve patient care, optimize resource allocation in healthcare settings, and advance inflammation-based diagnostics.

Recent filings

Filing Released Lang Actions
ViroGates announces its Annual Report 2020: Growing revenue and customer base - a robust platform for the future
Report Publication Announcement Classification · 95% confidence The document is a company announcement titled 'ViroGates announces its Annual Report 2020'. While it contains summary financial highlights, the text explicitly states: 'This announcement is a summary and should be read in conjunction with ViroGates' Annual Report for 2020, published on 24 March 2020.' It also includes an attachment link for the full report. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement (RPA) rather than the full Annual Report (10-K). FY 2020
2021-03-24 English
ViroGates announces its Annual Report 2020: Growing revenue and customer base - a robust platform for the future
Report Publication Announcement Classification · 100% confidence The document is a company announcement from ViroGates regarding the publication of their Annual Report 2020. It explicitly states, 'This announcement is a summary and should be read in conjunction with ViroGates’ Annual Report for 2020, published on 24 March 2020.' Because the document is an announcement of a report's release rather than the full report itself, it falls under the Report Publication Announcement (RPA) category.
2021-03-24 English
ViroGates announces its Annual Report 2020: Growing revenue and customer base - a robust platform for the future
Report Publication Announcement Classification · 95% confidence The document is a company announcement titled 'ViroGates announces its Annual Report 2020'. While it contains summary financial highlights, the text explicitly states: 'This announcement is a summary and should be read in conjunction with ViroGates' Annual Report for 2020, published on 24 March 2020.' It also includes an attachment link for the full report. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement (RPA) rather than the full Annual Report (10-K). FY 2020
2021-03-24 English
ViroGates announces CE-IVD approval for suPARnostic® TurbiLatex on the Abbott Alinity platform
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding a specific product development milestone (CE-IVD approval for a medical device). It does not fit into financial reporting categories like 10-K, IR, or ER, nor does it represent a corporate governance or management change. As it is a general regulatory/corporate announcement regarding business operations, it falls under the RNS (Regulatory Filings) category.
2021-03-15 English
ViroGates announces CE-IVD approval for suPARnostic® TurbiLatex on the Abbott Alinity platform
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding a specific product development milestone (CE-IVD approval for a medical device). It does not fit into financial reporting categories like 10-K or IR, nor is it a board change or dividend notice. As it is a general regulatory announcement regarding company operations and product status, it falls under the RNS (Regulatory Filings) category.
2021-03-15 English
ViroGates announces a new clinical routine customer in Greece
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding a new clinical routine customer in Greece. It does not fit into specific financial reporting categories like 10-K, ER, or IR, nor is it a report publication announcement (RPA) as it is the primary announcement itself. Since it is a general corporate announcement regarding business operations that does not fall into the other specialized categories, it is classified as a Regulatory Filing (RNS).
2021-03-03 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.